Sachin D. Patel discloses substantial share acquisition in Gujarat Themis Biosyn under SEBI Takeover Code
Under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Regulation 10(5) requires that when a person acquires shares crossing prescribed thresholds (5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%), a disclosure must be filed with the stock exchange within 2 trading days. Sachin D. Patel's filing with NSE indicates he has crossed one or more such thresholds. The timing (24 June 2026) and the identifiable acquirer suggest this is likely a single-purchaser acquisition in the pharmaceutical/biotech sector, now subject to public scrutiny and potential subsequent takeover obligations.
Why it mattersRegulation 10(5) disclosures mark critical shareholding milestones under the SEBI Takeover Code; the acquirer's identity, acquisition timing and quantum now trigger open-market scrutiny and potential competing bids or regulatory gating.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives - Corporate Actions Filing · official
- SEBI Official - Master Circular on Takeover Regulations · official
- NSE Listing Agreement & Rules · official
Related deals
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Trilegal acts on Berry Street - Healthify merger27 Aug 2026
- ChrysCapital-backed KIMS in talks to acquire minority stake in Renova Hospitals for $52M25-26 Aug 2026 · $52 million
- Mankind Pharma Limited: Other Restructuring26 Aug 2026
- Mankind Pharma Limited: Outcome of Board Meeting26 Aug 2026